Childhood, adolescent and young adult non‐Hodgkin lymphoma: state of the science

Pinkerton, Ross; Cairo, Mitchell S.; Cotter, Finbarr E.

doi:10.1111/bjh.14091

Cited by 13 publications

(6 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Awasthi , et al 2015, Barth , et al 2013, Cooney-Qualter , et al 2007, Shiramizu , et al 2015) Furthermore, targeting more specific molecular or cellular pathways in children and adolescents with mature B cell lymphoma should be studied in a cooperative setting to improve the long term OS in this poor risk group of patients. (Lee , et al 2017, Pinkerton , et al 2016)…”

Section: Discussionmentioning

confidence: 99%

Overall survival of children and adolescents with mature B cell non‐Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group

et al. 2018

Self Cite

View full text Add to dashboard Cite

We determined the risk factors associated with poor survival in children and adolescents with de novo mature B cell non-Hodgkin lymphoma (B-NHL) who had refractory or relapsed disease during or after the French-American-British mature lymphoma B (FAB/LMB) 96 multi-agent chemotherapy. Among the 1 111 registered on study, 104 patients (9·4%) had refractory disease or disease relapse after first complete remission. Among these 104 patients, 28 (27%) patients had refractory disease and 76 (73%) had relapsed disease. The estimated 1- and 2-year overall survival (OS) (95% confidence interval) was 31·5% (23·3-41·0%) and 22·3% (15·3-31·4%), respectively. Prognostic analysis of OS using a Cox multivariate model showed that factors independently associated with OS included lactate dehydrogenase ≥2 upper normal limit [hazard ratio (HR) = 2·86 (1·57-5·2), P = 0·0006]; time to failure (>6 months) [HR = 0·59 (0·36-0·97), P = 0·038]; and failure in bone marrow [HR = 2·78 (1·65-4·68), P = 0·0001]. New therapeutic strategies are required to significantly reduce refractory disease and disease relapse in patients with newly diagnosed mature B-NHL and, more importantly, there is a critical need to develop novel retrieval approaches in patients with chemotherapy-resistant disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Overall survival of children and adolescents with mature B cell non‐Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Epidemiology and Clinical Features ALK+ ALCL is a rare subtype of NHL, defined as a distinct type of peripheral T cell lymphoma (PTCL) in the current WHO classification [9]. It mostly affects children and young adults with a male predominance (male/female ratio: 3.0), accounting for 10-15% of pediatric and adolescent NHLs; it represents approximately 3% of adult NHLs [10]. Patients usually present at an advanced stage (stage III or IV), with severe systemic symptoms (75%) [11].…”

Section: T Cell Lymphomasmentioning

confidence: 99%

“…ALK+ ALCL is typically a nodal lymphoma (90% of cases), while extranodal involvement is observed in 60% of cases. The most common extranodal sites include skin (26%), bone (14%), soft tissue (15%), lung (14%), and BM (10-14%) [10,11]. First-line therapy for patients with ALK+ ALCL includes anthracycline-containing CHOP-like regimens or CHOP-like regimens with etoposide [12].…”

Section: T Cell Lymphomasmentioning

confidence: 99%

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma

et al. 2020

View full text Add to dashboard Cite

Reed–Sternberg cells (RSCs) are hallmarks of classic Hodgkin lymphoma (cHL). However, cells with a similar morphology and immunophenotype, so-called Reed–Sternberg-like cells (RSLCs), are occasionally seen in both B cell and T cell non-Hodgkin Lymphomas (NHLs). In NHLs, RSLCs are usually present as scattered elements or in small clusters, and the typical background microenviroment of cHL is usually absent. Nevertheless, in NHLs, the phenotype of RSLCs is very similar to typical RSCs, staining positive for CD30 and EBV, and often for B cell lineage markers, and negative for CD45/LCA. Due to different therapeutic approaches and prognostication, it is mandatory to distinguish between cHL and NHLs. Herein, NHL types in which RSLCs can be detected along with clinicopathological correlation are described. Moreover, the main helpful clues in the differential diagnosis with cHL are summarized.

show abstract

“…With intense, multi-agent chemotherapy regimens, survival rates for childhood BL have improved significantly in recent decades. Currently, greater than 90% of children diagnosed with BL are cured of their disease [ 1 , 2 ]. While highly curable, the therapy is quite toxic with high rates of acute toxicity including mucositis and infections.…”

Section: Introductionmentioning

confidence: 99%

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been implicated in Burkitt lymphomagenesis and increased PI3K/AKT activation has been associated with worse outcomes in adults with aggressive B-cell non-Hodgkin lymphoma (B-NHL). Inhibitors of the PI3K/AKT pathway have been approved for the treatment of refractory indolent B-NHL and continue to be investigated for treatment of aggressive B-NHLs. We investigated the activation of the PI3K/AKT pathway in a cell line model of resistant BL and the ability to target this pathway with small molecule inhibitors in BL cell lines. We found that cell lines resistant to rituximab and chemotherapy exhibited increased activation of PI3K/AKT and that inhibition of AKT or PI3K results in in vitro anti-lymphoma activity. To investigate the role of PI3K/AKT activation on the efficacy of cytotoxic chemotherapy, we exposed cells to inhibitors in combination with chemotherapy and noted a synergistic increase in response to chemotherapy. Overall these findings highlight the role of PI3K/AKT in chemotherapy resistance in BL cells and may represent a tractable therapeutic target.

show abstract

Childhood, adolescent and young adult non‐Hodgkin lymphoma: state of the science

Cited by 13 publications

References 83 publications

Overall survival of children and adolescents with mature B cell non‐Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group

Overall survival of children and adolescents with mature B cell non‐Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

Contact Info

Product

Resources

About